A study led by Dr. LI Chuanyun from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences (CAS) has revealed how recently evolved human-specific genes—critical for brain development and cognitive abilities—can be hijacked by cancer to drive tumor growth.

Two junior research groups at Ruhr University Bochum, Germany, have developed a drug complex that kills cancer cells in such a clever manner that they raise a red flag as they die. They signal to the immune system that something is seriously wrong with this type of cell. This teaches the immune cells to destroy such cancer cells—even if they are not in the vicinity of the original tumor. This could remove metastases that develop at distant sites in the body. Dr. Johannes Karges from the Department of Chemistry and Biochemistry and Dr. Carlos Plaza-Sirvent from the Department of Medicine present their findings in the Journal of Medicinal Chemistry on July 17, 2025.

Early-onset gastrointestinal (GI) cancers are rising at alarming rates worldwide and, in the U.S., are increasing faster than any other type of early-onset cancer, including breast cancer, according to two recent literature reviews from Dana-Farber Cancer Institute.

Impactful new research from the University of Ottawa's Faculty of Medicine could inform future therapeutic approaches targeting cells carrying damaged DNA and aimed at thwarting cancer resistance mechanisms.

The University of Virginia School of Medicine’s Harald Sontheimer, PhD, and Stanford’s Michelle Monje, MD, PhD, have received the 2025 International Prize in Translational Neuroscience from the Gertrud Reemtsma Foundation for their pioneering research in the emerging field of cancer neuroscience.